Evidence map›Paper›PMID 40624516›Full record

ArticleLipids in health and disease2025

Prevalence of dyslipidemia and its association with blood pressure control in Iranian hypertensive patients: insights from STEPS 2021.

Shervin Mossavarali, Yosra Azizpour, Ali Golestani, Nazila Rezaei, Sepehr Khosravi, Mina Mirzad, Pouria Khashayar, Ozra Tabatabaei-Malazy

Abstract read
In one paragraph

Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shervin Mossavarali *Non‑Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0009-0001-3579-8898
Yosra Azizpour *Non‑Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-3875-3871
Ali GolestaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-5192-0435
Nazila RezaeiNon‑Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-4241-1783
Sepehr KhosraviNon‑Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-5372-0787
Mina MirzadNon‑Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0009-0002-0634-3293
Pouria KhashayarSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.ORCID http://orcid.org/0000-0002-0736-2181
Ozra Tabatabaei-MalazyNon‑Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. tabatabaeiml@sina.tums.ac.ir.ORCID http://orcid.org/0000-0003-0188-9721

Funding

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran 1403-2-221-73074
6 · The paper itself

Abstract

backgroundGiven the association between dyslipidemia and hypertension and their significant impact on cardiovascular diseases (CVDs) in Middle Eastern countries, coordinated monitoring of these risk factors across the region is essential. This study aimed to assess the prevalence of dyslipidemia among hypertensive Iranians and explore its association with hypertension control.

methodsData from the Iranian STEPwise Approach to Non-communicable Disease (NCD) Risk Factor Surveillance (STEPS) 2021 survey, including questionnaires, physical measurements, laboratory tests, from a total of 5,997 participants, were analyzed. Hypertension was defined as the current use of antihypertensive medication or blood pressure ≥ 140/90 mmHg. Lipid markers, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), Non-HDL-C, and triglycerides (TG), were evaluated using the National Cholesterol Education Program Adult Treatment Panel III 2004 criteria. Associations between lipid markers and uncontrolled hypertension were assessed using a multivariable modified Poisson regression model, with results presented as adjusted prevalence ratio (APR) and 95% confidence interval (CI). All analyses were conducted utilizing STATA software version 14.2.

resultsThe prevalence of dyslipidemia among hypertensive Iranian adults was 86.4% [95% CI: 85.0, 87.6], with the most common abnormalities being low HDL-C 71.3% [95% CI: 69.6, 72.9], followed by hypertriglyceridemia 48.4% [95% CI: 46.5, 50.2], hypercholesterolemia 24.9% [95% CI: 23.3, 26.6], and high LDL-C 18.8% [95% CI: 17.3, 20.3]. In the multivariable model, TC, LDL-C, Non-HDL-C, TC/HDL-C, and LDL-C/HDL-C were significantly associated with uncontrolled hypertension in both males and females. Each 1 mmol/L increase in LDL-C was associated with a higher prevalence of uncontrolled hypertension by 1.07 [95% CI: 1.04, 1.09] in males and 1.05 [95% CI: 1.03, 1.07] in females; Non-HDL-C by 1.06 [95% CI: 1.04, 1.08] in males and 1.05 [95% CI: 1.03, 1.07] in females; TC by 1.06 [95% CI: 1.04, 1.08] in males and 1.05 [95% CI: 1.03, 1.07] in females; and TG by 1.02 [95% CI: 1.00, 1.03] in males.

conclusionsDyslipidemia is highly prevalent among hypertensive Iranian adults and may be associated with poor blood pressure control. In particular, low HDL-C emerged as the most frequent lipid abnormality and should be carefully assessed and managed as part of integrated, preventive hypertension care.

Indexed as

Blood PressureDyslipidemiasHypertensionAdultAgedAntihypertensive AgentsCholesterol, HDLCholesterol, LDLFemaleHumansIranMaleMiddle AgedPrevalenceRisk FactorsTriglyceridesAntihypertensive AgentsCholesterol, HDLCholesterol, LDLTriglyceridesDyslipidemiaHealth surveysHypertensionIranPrevalence

Identifiers

PMID40624516
PMCPMC12232805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.